Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

3.6%

2 terminated/withdrawn out of 56 trials

Success Rate

96.3%

+9.8% vs industry average

Late-Stage Pipeline

32%

18 trials in Phase 3/4

Results Transparency

56%

29 of 52 completed trials have results

Key Signals

29 with results

Enrollment Performance

Analytics

Phase 1

13(28.3%)

Phase 2

12(26.1%)

Phase 4

12(26.1%)

Phase 3

6(13.0%)

N/A

3(6.5%)

46Total

Phase 1(13)

Phase 2(12)

Phase 4(12)

Phase 3(6)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (56)

Showing 20 of 56 trials

NCT06576843Phase 2Completed

INDV-6001 Multiple-Dose Pharmacokinetic Study

Role: lead

NCT04995029Phase 4Completed

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

Role: lead

NCT05878210Completed

Evaluating the SUBLOCADE Treatment Exit Strategy

Role: lead

NCT06384157Phase 2Completed

Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Role: lead

NCT05860959Completed

SUBLOCADE Long-term Outcomes

Role: lead

NCT03993392Phase 4Completed

SUBLOCADE Rapid Initiation Study

Role: lead

NCT04060654Phase 4Completed

SUBLOCADE Rapid Initiation Extension Study

Role: lead

NCT03747341Phase 1Completed

Buprenorphine-Fentanyl Interaction Study

Role: lead

NCT05974046Phase 1Completed

Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

Role: lead

NCT05704543Phase 4Completed

Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

Role: lead

NCT04976855Phase 1Completed

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

Role: lead

NCT05694533Phase 1Completed

Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults

Role: lead

NCT04413552Phase 1Completed

INDV-2000 First in Human

Role: lead

NCT01075971Phase 2Completed

Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)

Role: lead

NCT00684073Phase 4Completed

Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)

Role: lead

NCT00756353Completed

Survey of Buprenorphine Use Among "Out of Care" Population in France (P04933)(COMPLETED)

Role: lead

NCT00723697Completed

Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)

Role: lead

NCT04815590Unknown

Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose

Role: collaborator

NCT04577144Terminated

An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term

Role: lead

NCT02535494Not ApplicableCompleted

Risks and Benefits of Naloxone Prescribing

Role: collaborator